Virtu Financial LLC bought a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 3,331 shares of the health services provider's stock, valued at approximately $309,000.
Other hedge funds also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC raised its position in Amedisys by 108.1% in the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock valued at $29,000 after purchasing an additional 161 shares during the period. MassMutual Private Wealth & Trust FSB increased its holdings in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock valued at $31,000 after buying an additional 120 shares during the last quarter. Fifth Third Bancorp increased its holdings in Amedisys by 68.1% in the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock valued at $32,000 after buying an additional 141 shares during the last quarter. UMB Bank n.a. boosted its stake in Amedisys by 100.0% in the first quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock valued at $36,000 after acquiring an additional 193 shares during the period. Finally, Johnson Financial Group Inc. acquired a new position in Amedisys in the fourth quarter valued at approximately $55,000. 94.36% of the stock is owned by hedge funds and other institutional investors.
Amedisys Stock Up 0.0%
Amedisys stock traded up $0.03 during mid-day trading on Tuesday, hitting $101.01. 1,060,057 shares of the company's stock were exchanged, compared to its average volume of 780,222. The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The stock has a market cap of $3.32 billion, a P/E ratio of 39.30, a P/E/G ratio of 1.34 and a beta of 0.89. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $101.02. The stock has a 50 day moving average of $98.15 and a two-hundred day moving average of $94.82.
Amedisys (NASDAQ:AMED - Get Free Report) last released its earnings results on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, beating the consensus estimate of $1.39 by $0.15. Amedisys had a net margin of 3.56% and a return on equity of 12.91%. The business had revenue of $621.86 million during the quarter, compared to analysts' expectations of $614.61 million. During the same quarter last year, the company earned $0.98 earnings per share. The firm's revenue was up 5.2% on a year-over-year basis. As a group, analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $100.50.
Check Out Our Latest Stock Analysis on Amedisys
Amedisys Profile
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also

Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.